AU2020392427B2 - Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof - Google Patents

Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof Download PDF

Info

Publication number
AU2020392427B2
AU2020392427B2 AU2020392427A AU2020392427A AU2020392427B2 AU 2020392427 B2 AU2020392427 B2 AU 2020392427B2 AU 2020392427 A AU2020392427 A AU 2020392427A AU 2020392427 A AU2020392427 A AU 2020392427A AU 2020392427 B2 AU2020392427 B2 AU 2020392427B2
Authority
AU
Australia
Prior art keywords
compound
hydrogen
nhr
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020392427A
Other languages
English (en)
Other versions
AU2020392427A1 (en
Inventor
Sylvain Cottens
Niall DICKINSON
Katarzyna Kaczanowska
Roman PLUTA
Michal Walczak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Captor Therapeutics SA
Original Assignee
Captor Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Captor Therapeutics SA filed Critical Captor Therapeutics SA
Publication of AU2020392427A1 publication Critical patent/AU2020392427A1/en
Application granted granted Critical
Publication of AU2020392427B2 publication Critical patent/AU2020392427B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020392427A 2019-11-27 2020-11-27 Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof Active AU2020392427B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL2019000109 2019-11-27
PLPCT/PL2019/000109 2019-11-27
PCT/EP2020/083596 WO2021105334A1 (en) 2019-11-27 2020-11-27 Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2020392427A1 AU2020392427A1 (en) 2022-06-16
AU2020392427B2 true AU2020392427B2 (en) 2024-03-07

Family

ID=69024572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020392427A Active AU2020392427B2 (en) 2019-11-27 2020-11-27 Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof

Country Status (7)

Country Link
US (1) US20240343706A1 (https=)
EP (1) EP4065571A1 (https=)
JP (1) JP7852923B2 (https=)
KR (1) KR20220106801A (https=)
CN (1) CN115023419A (https=)
AU (1) AU2020392427B2 (https=)
WO (1) WO2021105334A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022255888A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2024015340A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Cereblon ligands and uses thereof
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
KR20250130610A (ko) * 2022-12-06 2025-09-02 캡터 테라퓨틱스 에스.에이. 유비퀴틴 리가제 및 표적 mcl-1 단백질에 결합하는 이작용성 화합물을 사용하는 표적화된 단백질 분해
CN120530094A (zh) * 2023-01-12 2025-08-22 田边三菱制药株式会社 Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法
CN121843932A (zh) 2023-08-31 2026-04-10 先正达农作物保护股份公司 杀有害生物活性吲唑化合物
CN117224547B (zh) * 2023-09-12 2025-05-27 中国医科大学附属第一医院 一种小分子化合物dBET1在银屑病治疗中的应用
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149309A2 (de) * 2009-06-24 2010-12-29 Bayer Cropscience Ag Cycloalkylamidbenzoxa(thia)zole
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2019043214A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
WO2020006233A1 (en) * 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP4467143B1 (en) 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
IL302595A (en) 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3154386A1 (en) * 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149309A2 (de) * 2009-06-24 2010-12-29 Bayer Cropscience Ag Cycloalkylamidbenzoxa(thia)zole
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2019043214A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
WO2020006233A1 (en) * 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1212628-28-8; STN Entry date 21 Mar 2010; 1H-Benzimidazole-7-carboxamide, 5-[(ethylsulfonyl)amino]-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-1-methyl-2-phenyl- *
CAS Registry Number 1212671-36-7; STN Entry date 21 Mar 2010; 1H-Benzimidazole-7-carboxamide, 5-[(cyclohexylcarbonyl)amino]-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-1-(2-methoxyethyl)- *
CAS Registry Number 1212690-52-2; STN Entry date 21 Mar 2010; 1H-Benzimidazole-7-carboxamide, 5-(benzoylamino)-1-cyclopentyl-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]- *
CAS Registry Number 1609734-02-2; STN Entry date 5 Jun 2014; *
CAS Registry Number 2223739-15-7; STN Entry date 20 May 2018; 1H-Benzimidazole-7-carboxamide, 5-fluoro-N-(hexahydro-2-oxo-1H-azepin-3-yl)-N-methyl- *
CAS registry number: 1478129-99-5; date entered STN: 21 Nov 2013; Chemical name: N-(2,6-Dioxo-3-piperidinyl)-1H-indole-5-carboxamide *
CAS registry number: 1489856-35-0; date entered STN: 08 Dec 2013; Chemical name: N-(2,6-Dioxo-3-piperidinyl)-1H-benzimidazole-6-carboxamide *
CAS registry number: 1496481-02-7; date entered STN: 16 Dec 2013; Chemical name: N-(2,6-Dioxo-3-piperidinyl)-1H-indole-4-carboxamide *
CAS registry number: 1955017-85-2; date entered STN: 19 Jul 2016; Chemical name: 6-Cyclopropyl-1-(1,1-dimethylethyl)-N-(2,6-dioxo-3-piperidinyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 30 October 2013 (2013-10-30), XP002801735, Database accession no. 1466543-51-0 *
Lu et al., 'Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4', Chemistry & Biology. 2015, vol. 22, pages 755-763 *

Also Published As

Publication number Publication date
JP7852923B2 (ja) 2026-04-28
US20240343706A1 (en) 2024-10-17
EP4065571A1 (en) 2022-10-05
AU2020392427A1 (en) 2022-06-16
CN115023419A (zh) 2022-09-06
JP2023504445A (ja) 2023-02-03
WO2021105334A1 (en) 2021-06-03
KR20220106801A (ko) 2022-07-29

Similar Documents

Publication Publication Date Title
AU2020392427B2 (en) Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
AU2025203542A1 (en) Triaryl compounds for treatment of PD-L1 diseases
AU2023204712B2 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2022412827A1 (en) Heterocyclic compound having anti-tumor activity and use thereof
RU2358974C2 (ru) Производные имидазо-пиридина, обладающие сродством к рецептору меланокортина
JP7760167B2 (ja) セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
JP2021532077A (ja) セレブロン系機構に対抗する二量体免疫調節化合物
EA031573B1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
JP7853713B2 (ja) セレブロンに結合する新規な化合物、及びその使用方法
JP2020532539A (ja) 抗癌剤としての環状ジヌクレオチド
ES2732437T3 (es) Moduladores del receptor de CXCR7
CA3225285A1 (en) Pi3k.alpha. inhibitors and methods of use thereof
CN112839944B (zh) 用于治疗狂犬病的化合物及其方法
IL239119A (en) Diazole for Cuttings
EP4653436A1 (en) Heterocyclic compounds, preparation method therefor and use thereof
AU2025200332A1 (en) Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
KR102951756B1 (ko) 신규 트리시클릭 방향족 헤테로시클릭 화합물, 및 이의 제조 방법, 약학적 조성물과 응용
WO2021202900A1 (en) 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
AU2019339994B2 (en) Furo[3,4-b]pyrrole-containing BTK inhibitor
WO2005118583A1 (en) 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2001521895A (ja) 新規金属錯体
WO2022255889A1 (en) Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) Compounds which bind to cereblon, and use thereof
WO2025010326A2 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
CN121202853A (zh) 一类mitf转录因子蛋白降解剂及其用途